

Promotor

Prof dr Danny Schoors

Department of Cardiology UZ Brussel
Vrije Universiteit Brussel

Copromotor

Prof dr Hans Bonnier

Department of Cardiology UZ Brussel
Vrije Universiteit Brussel

Leden van de examencommissie

Prof dr Eric Eeckhout

Department of Cardiology, CHU Vaudois
University of Lausanne, Switzerland

Prof dr Jan Piek

Department of Cardiology, AMC
Universiteit van Amsterdam, Nederland

Prof dr Felix Zijlstra

Thoraxcentrum, UMCG
Universiteit Groningen, Nederland

Prof dr Pedro Brugada

Heart Rhythm Management Center UZ Brussel
Vrije Universiteit Brussel

Prof dr Luc Huyghens

Department of Intensive Care Medicine UZ Brussel
Vrije Universiteit Brussel

Prof dr Guy Van Camp

Department of Cardiology UZ Brussel
Vrije Universiteit Brussel

Prof dr Bart Keymeulen, voorzitter

Diabetes Research Center
Vrije Universiteit Brussel



Vrije Universiteit Brussel

FACULTEIT GENEESKUNDE EN FARMACIE

Doctoraat in de Medische Wetenschappen

Academiejaar 2009-2010

UITNODIGING

Voor de openbare verdediging van het
doctoraatsproefschrift van

Paul VERMEERSCH

vrijdag 17 september 2010

U wordt vriendelijk uitgenodigd op de openbare verdediging van het proefschrift van

Paul VERMEERSCH

'Percutaneous coronary intervention for the treatment of saphenous vein grafts'

Op **vrijdag 17 september 2010**
om **17.30 uur** in auditorium **P. Brouwer**
van de Faculteit Geneeskunde & Farmacie,
Laarbeeklaan 103, 1090 Brussel

Situering van het proefschrift

In the beginning of this millennium , the adjunct of drugs directly onto metallic stents made that stents were not only used to scaffold the vessel, but also to elute drugs with the potential to inhibit the processes leading to restenosis . A restenosis rate of less than 10% was achieved, however some concerns related to the safety, possibly linked to the higher stent thrombosis rate , were raised.

We focused on the use of drug eluting stents for the treatment of diseased saphenous vein grafts, usually excluded from the randomized trials.

The purpose of this research was to assess acute and long term efficacy and safety of drug-eluting stents.

Saphenous vein grafts have always been, considered high risk, both for their inherent risks of acute embolization resulting in distal myocardial damage and for increased restenosis, higher than in native coronary arteries. We conducted the first randomized trial comparing bare metal stents and sirolimus eluting stents in saphenous vein grafts. The results of this trial showed a significant reduction of restenosis at 6 months, however, on the long term increased major cardiac event rates were more prevalent in the drug eluting stent group.

Curriculum Vitae

Paul Vermeersch was born on 28th July, 1962 in Brugge .

He obtained his MD diploma at the university of Ghent in 1987 with summa cum laude.

He became a resident in cardiology at the Sint-Antonius hospital , Nieuwegein , the Netherlands.

Since 1993 he is registered as a cardiologist in Belgium. From 1994 on he is working as a interventional cardiologist in the Middelheim hospital, Antwerpen. He is a fellow of the European society of cardiology.

His thesis resulted from randomized trials done in the field of the use of drug eluting stents in diseased saphenous vein grafts.

This resulted in several articles in international peer reviewed journals.